{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T19:40:20Z","timestamp":1739302820217,"version":"3.37.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1007\/s11926-009-0038-9","type":"journal-article","created":{"date-parts":[[2009,8,17]],"date-time":"2009-08-17T01:51:07Z","timestamp":1250473867000},"page":"270-277","source":"Crossref","is-referenced-by-count":12,"title":["Update on the treatment of peripheral arthritis in psoriatic arthritis"],"prefix":"10.1007","volume":"11","author":[{"given":"Enrique R.","family":"Soriano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,8,18]]},"reference":[{"key":"38_CR1","first-page":"1354","volume":"35","author":"Y. Alamanos","year":"2008","unstructured":"Alamanos Y, PV Voulgari A, A Drosos: Incidence and prevalence of psoriatic arthritis: a systematic review. J Rheumatol 2008, 35:1354\u20131358.","journal-title":"J Rheumatol"},{"key":"38_CR2","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","volume":"64","author":"D.D. Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, et al.: Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005, 64:ii14\u2013ii17.","journal-title":"Ann Rheum Dis"},{"key":"38_CR3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/art.24172","volume":"61","author":"F.C. Wilson","year":"2009","unstructured":"Wilson FC, Icen M, Crowson CS, et al.: Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 2009, 61:233\u2013239.","journal-title":"Arthritis Rheum"},{"key":"38_CR4","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/rheumatology\/keg217","volume":"42","author":"N.J. McHugh","year":"2003","unstructured":"McHugh NJ, Balachrishnan C, Jones SM: Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 2003, 42:778\u2013783.","journal-title":"Rheumatology (Oxford)"},{"key":"38_CR5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/ard.62.1.68","volume":"62","author":"R. Queiro-Silva","year":"2003","unstructured":"Queiro-Silva R, Torre-Alonso JC, Tinture-Eguren T, Lopez-Lagunas I: A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 2003, 62:68\u201370.","journal-title":"Ann Rheum Dis"},{"key":"38_CR6","first-page":"1228","volume":"33","author":"D.D. Gladman","year":"2006","unstructured":"Gladman DD, Mease PJ: Towards international guidelines for the management of psoriatic arthritis. J Rheumatol 2006, 33:1228\u20131230.","journal-title":"J Rheumatol"},{"key":"38_CR7","first-page":"1422","volume":"33","author":"E.R. Soriano","year":"2006","unstructured":"Soriano ER, McHugh NJ: Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006, 33:1422\u20131430.","journal-title":"J Rheumatol"},{"key":"38_CR8","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/art.22379","volume":"56","author":"D.D. Gladman","year":"2007","unstructured":"Gladman DD, Mease PJ, Ritchlin CT, et al.: Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007, 56:476\u2013488.","journal-title":"Arthritis Rheum"},{"key":"38_CR9","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/ard.2005.045658","volume":"65","author":"A. Kavanaugh","year":"2006","unstructured":"Kavanaugh A, Antoni CE, Gladman D, et al.: The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006, 65:1038\u20131043.","journal-title":"Ann Rheum Dis"},{"key":"38_CR10","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"P.J. Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, et al.: Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52:3279\u20133289.","journal-title":"Arthritis Rheum"},{"key":"38_CR11","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"P.J. Mease","year":"2004","unstructured":"Mease PJ, Kivitz AJ, Burch FX, et al.: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264\u20132272.","journal-title":"Arthritis Rheum"},{"key":"38_CR12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/ard.2007.072652","volume":"67","author":"V. Ravindran","year":"2008","unstructured":"Ravindran V, Scott DL, Choy EH: A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 2008, 67:855\u2013859.","journal-title":"Ann Rheum Dis"},{"key":"38_CR13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","volume":"58","author":"A. Gottlieb","year":"2008","unstructured":"Gottlieb A, Korman NJ, Gordon KB, et al.: Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008, 58:851\u2013864.","journal-title":"J Am Acad Dermatol"},{"key":"38_CR14","doi-asserted-by":"crossref","unstructured":"Ritchlin CT, Kavanaugh A, Gladman DD, et al.: Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2008, Oct 24 (Epub ahead of print).","DOI":"10.1136\/ard.2008.094946"},{"key":"38_CR15","first-page":"70","volume":"24","author":"C. Salvarani","year":"2006","unstructured":"Salvarani C, Olivieri I, Pipitone N, et al.: Recommendations of the Italian Society for Rheumatology for the use of biologic (TNF-alpha blocking) agents in the treatment of psoriatic arthritis. Clin Exp Rheumatol 2006, 24:70\u201378.","journal-title":"Clin Exp Rheumatol"},{"key":"38_CR16","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jbspin.2007.10.003","volume":"74","author":"T. Pham","year":"2007","unstructured":"Pham T, Fautrel B, Dernis E, et al.: Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine 2007, 74:638\u2013646.","journal-title":"Joint Bone Spine"},{"key":"38_CR17","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/rheumatology\/keh514","volume":"44","author":"S. Kyle","year":"2005","unstructured":"Kyle S, Chandler D, Griffiths CE, et al.: Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology (Oxford) 2005, 44:390\u2013397.","journal-title":"Rheumatology (Oxford)"},{"key":"38_CR18","first-page":"2273","volume":"34","author":"W.P. Maksymowych","year":"2007","unstructured":"Maksymowych WP, Gladman D, Rahman P, et al.: The Canadian Rheumatology Association\/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis: a national multidisciplinary stakeholder project. J Rheumatol 2007, 34:2273\u20132284.","journal-title":"J Rheumatol"},{"key":"38_CR19","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11926-007-0072-4","volume":"9","author":"D. McCarey","year":"2007","unstructured":"McCarey D, McInnes IB: Psoriatic arthritis: current topics. Curr Rheumatol Rep 2007, 9:442\u2013448.","journal-title":"Curr Rheumatol Rep"},{"key":"38_CR20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10067-007-0787-7","volume":"27","author":"R. Scarpa","year":"2008","unstructured":"Scarpa R, Peluso R, Atteno M, et al.: The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol 2008, 27:823\u2013826.","journal-title":"Clin Rheumatol"},{"key":"38_CR21","first-page":"469","volume":"35","author":"V. Chandran","year":"2008","unstructured":"Chandran V, Schentag CT, Gladman DD: Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol 2008, 35:469\u2013471.","journal-title":"J Rheumatol"},{"key":"38_CR22","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/rheumatology\/37.7.760","volume":"37","author":"P. Rahman","year":"1998","unstructured":"Rahman P, Gladman DD, Cook RJ, et al.: Radiological assessment in psoriatic arthritis. Br J Rheumatol 1998, 37:760\u2013765.","journal-title":"Br J Rheumatol"},{"key":"38_CR23","first-page":"241","volume":"22","author":"M. Abu-Shakra","year":"1995","unstructured":"Abu-Shakra M, Gladman DD, Thorne JC, et al.: Long-term methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995, 22:241\u2013245.","journal-title":"J Rheumatol"},{"key":"38_CR24","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","volume":"50","author":"J.P. Kaltwasser","year":"2004","unstructured":"Kaltwasser JP, Nash P, Gladman D, et al.: Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004, 50:1939\u20131950.","journal-title":"Arthritis Rheum"},{"key":"38_CR25","first-page":"881","volume":"25","author":"D. Malesci","year":"2007","unstructured":"Malesci D, Tirri T, Buono R, La Montagna G: Leflunomide in psoriatic arthritis: a retrospective study of discontinuation rate in daily clinical practice compared with methotrexate. Clin Exp Rheumatol 2007, 25:881\u2013884.","journal-title":"Clin Exp Rheumatol"},{"key":"38_CR26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/rheumatology\/36.1.95","volume":"36","author":"G. Jones","year":"1997","unstructured":"Jones G, Crotty M, Brooks P: Psoriatic arthritis: a quantitative overview of therapeutic options. The Psoriatic Arthritis Meta-Analysis Study Group. Br J Rheumatol 1997, 36:95\u201399.","journal-title":"Br J Rheumatol"},{"key":"38_CR27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/art.22467","volume":"57","author":"H. Marzo-Ortega","year":"2007","unstructured":"Marzo-Ortega H, Green MJ, Keenan AM, et al.: A randomized controlled trial of early intervention with intraarticular corticosteroids followed by sulfasalazine versus conservative treatment in early oligoarthritis. Arthritis Rheum 2007, 57:154\u2013160.","journal-title":"Arthritis Rheum"},{"key":"38_CR28","first-page":"589","volume":"13","author":"A. Spadaro","year":"1995","unstructured":"Spadaro A, Riccieri V, Sili-Scavalli A, et al.: Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995, 13:589\u2013593.","journal-title":"Clin Exp Rheumatol"},{"key":"38_CR29","first-page":"2274","volume":"28","author":"C. Salvarani","year":"2001","unstructured":"Salvarani C, Macchioni P, Olivieri I, et al.: A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001, 28:2274\u20132282.","journal-title":"J Rheumatol"},{"key":"38_CR30","doi-asserted-by":"crossref","unstructured":"Grimshaw JM, Winkens RA, Shirran L, et al.: Interventions to improve outpatient referrals from primary care to secondary care. Cochrane Database Syst Rev 2005: CD005471.","DOI":"10.1002\/14651858.CD001482.pub2"},{"key":"38_CR31","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/01.bor.0000231901.19795.8a","volume":"18","author":"A. Kavanaugh","year":"2006","unstructured":"Kavanaugh A, Tutuncu Z, Catalan-Sanchez T: Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis. Curr Opin Rheumatol 2006, 18:347\u2013353.","journal-title":"Curr Opin Rheumatol"},{"key":"38_CR32","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"C.E. Antoni","year":"2005","unstructured":"Antoni CE, Kavanaugh A, Kirkham B, et al.: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005, 52:1227\u20131236.","journal-title":"Arthritis Rheum"},{"key":"38_CR33","first-page":"869","volume":"35","author":"C.E. Antoni","year":"2008","unstructured":"Antoni CE, Kavanaugh A, van der Heijde D, et al.: Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008, 35:869\u2013876.","journal-title":"J Rheumatol"},{"key":"38_CR34","first-page":"712","volume":"33","author":"P.J. Mease","year":"2006","unstructured":"Mease PJ, Kivitz AJ, Burch FX, et al.: Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006, 33:712\u2013721.","journal-title":"J Rheumatol"},{"key":"38_CR35","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/ard.2008.092767","volume":"68","author":"P.J. Mease","year":"2009","unstructured":"Mease PJ, Ory P, Sharp JT, et al.: Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009, 68:702\u2013709.","journal-title":"Ann Rheum Dis"},{"key":"38_CR36","doi-asserted-by":"crossref","unstructured":"Anandarajah AP, Ory P, Salonen D, et al.: Effect of adalimumab on joint disease features of patients with psoriatic arthritis detected by Magnetic Resonance Imaging. Ann Rheum Dis 2009 Feb 9 (Epub ahead of print).","DOI":"10.1136\/ard.2008.100149"},{"key":"38_CR37","first-page":"2183","volume":"32","author":"C. Delaunay","year":"2005","unstructured":"Delaunay C, Farrenq V, Marini-Portugal A, et al.: Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol 2005, 32:2183\u20132185.","journal-title":"J Rheumatol"},{"key":"38_CR38","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/ard.2007.073569","volume":"66","author":"F. Conti","year":"2007","unstructured":"Conti F, Ceccarelli F, Marocchi E, et al.: Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 2007, 66, 1393\u20131397.","journal-title":"Ann Rheum Dis"},{"key":"38_CR39","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1136\/ard.2008.091900","volume":"67","author":"F. Conti","year":"2008","unstructured":"Conti F, Ceccarelli F, Priori R, et al.: Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha. Ann Rheum Dis 2008, 67:1787\u20131790.","journal-title":"Ann Rheum Dis"},{"key":"38_CR40","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","volume":"60","author":"A. Kavanaugh","year":"2009","unstructured":"Kavanaugh A, McIness I, Mease P, et al.: Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009, 60:976\u2013986.","journal-title":"Arthritis Rheum"},{"key":"38_CR41","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/09546630802441234","volume":"20","author":"J.M. Ko","year":"2009","unstructured":"Ko JM, Gottlieb AB, Kerbleski JF: Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 2009, 20:100\u2013108.","journal-title":"J Dermatolog Treat"},{"key":"38_CR42","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/art.23835","volume":"59","author":"A.N. Collamer","year":"2008","unstructured":"Collamer AN, Guerrero KT, Henning JS, Battafarano DF: Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008, 59:996\u20131001.","journal-title":"Arthritis Rheum"},{"key":"38_CR43","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/rheumatology\/kel147","volume":"45","author":"N.J. Bansback","year":"2006","unstructured":"Bansback NJ, Ara R, Barkham N, et al.: Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology (Oxford) 2006, 45:1029\u20131038.","journal-title":"Rheumatology (Oxford)"},{"key":"38_CR44","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/rheumatology\/kem221","volume":"46","author":"Y. Bravo Vergel","year":"2007","unstructured":"Bravo Vergel Y, Hawkins NS, Claxton K, et al.: The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology (Oxford) 2007, 46:1729\u20131735.","journal-title":"Rheumatology (Oxford)"},{"key":"38_CR45","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/rheumatology\/ken320","volume":"47","author":"I. Olivieri","year":"2008","unstructured":"Olivieri I, de Portu S, Salvarani C, et al.: The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology (Oxford) 2008, 47:1664\u20131670.","journal-title":"Rheumatology (Oxford)"},{"key":"38_CR46","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/art.21870","volume":"54","author":"P.J. Mease","year":"2006","unstructured":"Mease PJ, Gladman DD, Keystone EC: Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebocontrolled study. Arthritis Rheum 2006, 54:1638\u20131645.","journal-title":"Arthritis Rheum"},{"key":"38_CR47","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jaad.2008.09.050","volume":"60","author":"P.J. Mease","year":"2009","unstructured":"Mease PJ, Reich K: Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2009, 60:402\u2013411.","journal-title":"J Am Acad Dermatol"},{"key":"38_CR48","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.22489","volume":"56","author":"A.M. Turkiewicz","year":"2007","unstructured":"Turkiewicz AM, Moreland LW: Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum 2007, 56:1051\u20131066.","journal-title":"Arthritis Rheum"},{"key":"38_CR49","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2310\/7750.2007.00006","volume":"11","author":"K.A. Papp","year":"2007","unstructured":"Papp KA, Caro I, Leung HM, et al.: Efalizumab for the treatment of psoriatic arthritis. J Cutan Med Surg 2007, 11:57\u201366.","journal-title":"J Cutan Med Surg"},{"key":"38_CR50","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1172\/JCI5857","volume":"103","author":"J.R. Abrams","year":"1999","unstructured":"Abrams JR, Lebwohl MG, Guzzo CA, et al.: CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999, 103:1243\u20131252.","journal-title":"J Clin Invest"},{"key":"38_CR51","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","volume":"373","author":"A. Gottlieb","year":"2009","unstructured":"Gottlieb A, Menter A, Mendelsohn A, et al.: Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009, 373:633\u2013640.","journal-title":"Lancet"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-009-0038-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-009-0038-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-009-0038-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T19:26:36Z","timestamp":1739301996000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-009-0038-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["38"],"URL":"https:\/\/doi.org\/10.1007\/s11926-009-0038-9","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"type":"print","value":"1523-3774"},{"type":"electronic","value":"1534-6307"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}